Project Term: August 18, 2014 - TBD
In August 2014, LLS made an equity investment in OncoPep which is currently supporting "A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma." Smoldering multiple myeloma is the asymptomatic stage of multiple myeloma that has a high risk of progressing to full-blown multiple myeloma. PVX-410 is made of multiple peptides to target the tumor cell heterogeneity observed in all cancers, particularly MM, and decrease the likelihood of tumor cells developing resistance by targeting multiple antigens found on the surface of MM cells simultaneously. Furthermore, targeting multiple antigens increases the probability of an immune response in the target patient population. Citarinostat is an orally active, small-molecule histone deacetylase (HDAC) inhibitor which is being combined here to further augment the immune activity of the vaccine. The FDA has approved lenalidomide as a treatment option for SMM. Lenalidomide is being added to the combination of the vaccine and Citarinostat because it is hypothesized that co-administration would further enhance the T cell-mediated immune response induced by PVX-410.
For additional information, please visit https://lls.org/therapy-acceleration-program-portfolio